

Amendments to the Claims

The following listing of the claims replaces all prior listings.

1. (Currently amended) A method for treating a subject having nephropathy comprising:
administering to an individual in need of such treatment an effective amount of a GLP-1, an agonist, analog, or derivative thereof having at least 70% amino acid sequence homology to GLP-1 and having at least one action of GLP-1.
2. (Previously Presented) The method of claim 1 wherein said GLP-1 agonist analog is 90% identical to SEQ ID NO: 1.
3. (Cancelled)
4. (Previously Presented) The method of claim 1 wherein the composition is administered in a dose of from about 0.001 pmol/kg to 20 nmoL/kg.
5. (Previously Presented) The method of claim 1 wherein the composition is administered in a dose of from about 0.001 µg/kg/dose to about 1.0 µg/kg/dose.
6. (Previously Presented) The method of claim I wherein the composition is administered in a dose sufficient to achieve a therapeutic plasma level of at least 40 pg/ml.
7. (Previously Presented) The method of claim I wherein the compound is administered parenterally.
8. (Previously Presented) The method of claim 4 wherein the compound is administered intravenously in a dose of from about 0.1 pmol/kg/min up to about 10 pmol/kg/min.
9. (Previously Presented) The method of claim 1 wherein the compound is administered subcutaneously in a dose of from about 0.1 pmol/kg/min to 75 pmol/kg/min.
10. (Currently amended) A method for preventing or treating progression of End Stage Renal Disease in a subject having nephropathy comprising

administering to an individual in need of such treatment an effective amount of GLP-1, an agonist, analog, or derivative thereof having at least 70% amino acid sequence homology to GLP-1 and having at least one action of GLP-1.

11. (Previously Presented) The method of claim 10 wherein said GLP-1 agonist analog is 90% identical to SEQ ID NO:1.

12. (Cancelled)

13. (Previously Presented) The method of claim 10 wherein the composition is administered in a dose of from about 0.001 pmol/kg to 20 nmol/kg.

14. (Previously Presented) The method of claim 10 wherein the composition is administered in a dose of from about 0.001 µg/kg/dose to about 1.0 µg/kg/dose.

15. (Previously Presented) The method of claim 10 wherein the composition is administered in a dose sufficient to achieve a therapeutic plasma level of at least 40 pg/mL.

16. (Previously Presented) The method of claim 10 wherein the compound is administered parenterally.

17. (Previously Presented) The method of claim 13 wherein the compound is administered intravenously in a dose of from about 0.1 pmol/kg/min up to about 10 pmol/kg/min.

18. (Previously Presented) The method of claim 1 wherein the compound is administered subcutaneously in a dose of from about 0.1 pmol/kg/min to 75 pmol/kg/min.

19-27. (Canceled)

28. (Currently amended) A method for reducing proteinuria in a patient comprising administering to an individual in need of such treatment an effective amount of a GLP-1, an agonist, analog, or derivative thereof having at least 70% amino acid sequence homology to GLP-1 and having at least one action of GLP-1.

29. (Previously Presented) The method of claim 28 wherein said GLP-1 agonist analog is 90% identical to SEQ ID NO: 1.

30. (Cancelled)

31. (Previously Presented) The method of claim 28 wherein the composition is administered in a dose of from about 0.001 pmol/kg to 20 nmol/kg.

32. (Previously Presented) The method of claim 28 wherein the composition is administered in a dose of from about 0.001 µg/kg/dose to about 1.0 µg/kg/dose.

33. (Previously Presented) The method of claim 28 wherein the composition is administered in a dose sufficient to achieve a therapeutic plasma level of at least 40 pg/ml.

34. (Previously Presented) The method of claim 28 wherein the compound is administered parenterally.

35. (Previously Presented) The method of claim 31 wherein the compound is administered intravenously in a dose of from about 0.1 pmol/kg/min up to about 10 pmol/kg/min.

36. (Previously Presented) The method of claim 28 wherein the compound is administered subcutaneously in a dose of from about 0.1 pmol/kg/min to 75 pmol/kg/min.

37. (Currently amended) A method for preventing or slowing progression of glomerulosclerosis in a subject comprising administering to an individual in need of such treatment an effective amount of GLP-1, an agonist, analog, or derivative thereof having at least 70% amino acid sequence homology to GLP-1 and having at least one action of GLP-1.

38. (Previously Presented) The method of claim 37 wherein said GLP-1 agonist analog is 90% identical to SEQ ID NO:1.

39. (Cancelled)

40. (Previously Presented) The method of claim 37 wherein the composition is administered in a dose of from about 0.001 pmol/kg to 20 nmol/kg.

41. (Previously Presented) The method of claim 37 wherein the composition is administered in a dose of from about 0.001 µg/kg/dose to about 1.0 µg/kg/dose.

42. (Previously Presented) The method of claim 37 wherein the composition is administered in a dose sufficient to achieve a therapeutic plasma level of at least 40 pg/ml.

43. (Previously Presented) The method of claim 37 wherein the compound is administered parenterally.

44. (Previously Presented) The method of claim 40 wherein the compound is administered intravenously in a dose of from about 0.1 pmol/kg/min up to about 10 pmol/kg/min.

45. (Previously Presented) The method of claim 37 wherein the compound is administered subcutaneously in a dose of from about 0.1 pmol/kg/min to 75 pmol/kg/min.

46. (Previously Presented) The method of claim 1 wherein the nephropathy is caused by diabetes, insulin resistance, or hypertension.

47. (Previously Presented) The method of claim 1 wherein said GLP-1 agonist analog is 95% identical to SEQ ID NO:1.

48. (Previously Presented) The method of claim 10 wherein said GLP-1 agonist analog is 95% identical to SEQ ID NO:1.

49. (Previously Presented) The method of claim 19 wherein said GLP-1 agonist analog is 95% identical to SEQ IDNO:1.

50. (Previously Presented) The method of claim 28 wherein said GLP-1 agonist analog is 95% identical to SEQ ID NO:1.

51. (Previously Presented) The method of claim 37 wherein said GLP-1 agonist analog is 95% identical to SEQ ID NO:1.

52. (Previously Presented) The method of claim 1 wherein said GLP-1 agonist analog is SEQ ID NO: 1.

53. (Previously Presented) The method of claim 10 wherein said GLP-1 agonist analog is SEQ ID NO:1.

54. (Previously Presented) The method of claim 19 wherein said GLP-1 agonist analog is SEQ ID NO:1.

55. (Previously Presented) The method of claim 28 wherein said GLP-1 agonist analog is SEQ ID NO:1.

56. (Previously Presented) The method of claim 37 wherein said GLP-1 agonist analog is SEQ ID NO: 1.